doi: 10.3390/ijms27062876
Less than 5% body weight loss after 16 or more weeks at a therapeutic dose (10mg or above) constitutes a poor response
GLP 1 Drug Biosimilar Market Size, Share & Trends Analysis by Reference Biologic (Semaglutide Biosimilar, Liraglutide Biosimilar, Exenatide Biosimilar, Dulaglutide Biosimilar), by Formulation (Injectable Pen, Oral Tablet, Patch & Implant), by Distribution (Retail Pharmacy, Mail-Order & Specialty Pharmacy, Hospital & Clinic), and Segment Forecasts, 2026 to 2035 GLP-1 biosimilars are biological medicines developed to be highly similar in quality, safety, and efficacy to the originator GLP-1 receptor agonists, such as semaglutide, liraglutide, and dulaglutide
And to everyone's surprise, the horse won the race
Clinical Evaluation A thorough history and physical examination are key
Understanding these motivations helps clarify whether alternating is the right solution or whether better alternatives exist